Victor Musiime
ID: UNCST-2021-R013794
|
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
REFNo: HS5637ES
1. To demonstrate superiority of
treatment with etavopivat
versus placebo in adolescents
and adults with SCD.
2. To evaluate clinical efficacy
measures of etavopivat treatment
versus placebo in adolescents
and adults with SCD
3. To assess clinically meaningful
improvement in fatigue and
functional exercise capacity
and QOL measures of
adolescents and adults with
SCD taking etavopivat
treatment compared to placebo
|
Wakiso, Sabagabo
Kampala, Mulago
Jinja, Jinja
|
Uganda |
2025-03-14 17:26:26 |
2028-03-14 |
408 |
12-17, 18 and above, male female all tribes |
Novo Nordisk A/S |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Margaret Nagawa
ID: UNCST-2022-R009705
|
EARLY NUTRITIONAL INTERVENTION FOR NUTRITIONALLY AT-RISK INFANTS UNDER 6 MONTHS OF AGE TO REDUCE MALNUTRITION IN THE FIRST YEAR OF LIFE
REFNo: HS3503ES
5. To assess the maternal and health worker perceptions on the integrated intervention package.,4. To assess the effect of an early integrated family intervention program for LBW and undernourished children u6m on growth in the first year of life.,3. To understand the barriers and facilitators to the integration of maternal mental health care and community-based management of malnutrition in infants u6m of age.,2. To assess the prevalence of maternal mental health among caregivers of u6m infants.,1. To determine the factors associated with malnutrition among infants u6m of age and challenges caregivers of LBW and undernourished infants face. ,2. To assess the prevalence of malnutrition among infants u6m and their associations, To assess the effect of an early integrated nutrition intervention for nutritionally at-risk infants u6m of age in reducing malnutrition in the first year of life. ,
|
Adjumani, Adjumani
|
Uganda |
2025-03-14 16:37:34 |
2028-03-14 |
300 mother baby pairs |
Infants under 6 months of age. and caregivers of infants under six months of age.
sex: males and females
Tribe: refugees and host communities |
self funded |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Schola Matovu Nakachwa
ID: UNCST-2022-R011040
|
Development and Testing of BAJJAJJA: An Intervention to Promote Economic Empowerment and Health of Grandmothers who Provide Primary Care for Grandchildren in Uganda
REFNo: SS3611ES
Main Objective
The study’s objective is to refine and test the feasibility and acceptability of my innovative intervention, BAJJAJJA: Building A Joint Action for JaJJAs which couples an income- generating activity (IGA) with nurse-facilitated group health coaching. This objective is informed by the NIH Stage Model of behavioral intervention development.
Specific Objectives
Aim 1: To refine and adapt the BAJJAJJA intervention through a collaborative and iterative feedback process with a diverse community group of 18 members. In a series of sessions, I will iteratively engage diverse community groups (nurses, local officials, IGA experts, and GMCs) and use cognitive interviewing to gain feedback on the appropriateness of study measures, content, delivery, and intervention format.
Aim 2: To test the feasibility, acceptability, and preliminary efficacy of the BAJJAJJA intervention in improving economic and health outcomes among 24 Ugandan GMCs. Over a 12-month period and at three time points of assessment, I will use a mixed methodology with a quasi-experimental design to collect data that will be examined to assess the feasibility, acceptability, and preliminary efficacy of the intervention on participants’ household income and health outcomes.
Aim 3: To explore the barriers and facilitators to (3a) maintenance of the BAJJAJJA individual intervention benefits (e.g., physical activity level and frequency) and (3b) sustainability of the IGA activities (e.g., grandmothers’ accessing external supports such as community resources) at 6 months post-intervention. Following a mixed methods approach, the 24 GMCs from Aim 2 will be interviewed to further evaluate the long-term maintenance and sustainability of the intervention. Health assessments, interviews, and IGA site visits will be used to explore the intervention outcomes and benefits at 6 months post-intervention.
|
Buikwe, Kiteza
|
USA |
2025-03-10 12:23:29 |
2028-03-10 |
24 Grandmother Caregivers |
1. Grandmothers:
Ugandan GMCs who are (a) > 50 years (considering the average reproductive age range in Uganda of 15-49 years), (b) Luganda-speaking (commonly spoken language), (c) primary caregivers for at least one minor grandchild (< 18 years) for > 6 months, and (d) able to perform activities of daily living (e.g., cooking, bathing) without assistance.
2.Community Advisory Board:
10 key informants: Local elected community leaders ( LCs), healthcare professionals, nurses from local health centers and a village health team member, IGA experts, and grandmothers. Participants will be identified by LC leaders or referred by other participants using a snowball sampling technique.
Participants are female (grandmother caregivers) with no tribal restrictions as long as she can speak luganda
|
NIH JOHN E FORGATY International Center |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
|
Randomized trial to evaluate the efficacy and safety of select therapeutic agents in the treatment of Ebola Disease (TOKOMEZA - Ebola Disease Therapeutics)
REFNo: HS5686ES
This is an open-label, adaptive, randomised platform clinical trial to evaluate the impact of 278 potential treatments on mortality in patients with Ebola Disease
|
All Districts, Not specific
|
Uganda |
2025-03-07 18:39:19 |
2028-03-07 |
180 |
All age groups, sex, and tribes that are eligible for recruitment. |
Ministry of Health of Uganda and World Health Organization |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO→ VERSUS PLACEBO IN COMBINATION WITH PHESGO→ AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA‑MUTATED HER2‑POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (INAVO122)
REFNo: HS5649ES
This study will enrol particpants
|
Kampala, Mulago
|
Uganda |
2025-03-07 18:26:49 |
2028-03-07 |
20 |
Adult females above 18 years of age with breast cancer |
F.Hoffman La Roche |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
